Back to reducing infections from injection drug use
Syringe Exchange Programs C.R. S. §25-1-520
Drug Paraphernalia Law Exemption, C.R.S. §18-18-430.5
Due to a 2020 amendment, a pharmacist or pharmacy technician who sells non-prescription syringes is also exempt pursuant to section 12-280-123 (4).
911 Good Samaritan Law, C.R.S. §18-1-711
Third Party Naloxone, C.R.S. §18-1-712
Naloxone Standing Orders, C.R.S. §12-36-117.7
Needle-stick Prevention C.R.S., §18-18-428
Coverage for Opiate Antagonists Provided by a Hospital C.R.S., §10-16-154
Signed into law July 13, 2020, this law requires health insurance carriers to reimburse a hospital if the facility provides a covered person with naloxone upon discharge.
Pharmacy Exemption to Prescription Requirement C.R.S., §12-280-123
Signed into law July 13, 2020, this law requires a pharmacist to notify an individual dispensed an opioid about the availability of opiate antagonists to reverse an overdose. If an individual to whom an opioid is being dispensed chooses to accept the pharmacist’s offer for an opiate antagonist, the pharmacist shall counsel the individual on how to use the opiate antagonist in the event of an overdose. A pharmacist or pharmacy technician may sell a nonprescription syringe or needle to any person.
School Employee or Agent Administration of Opiate Antagonists C.R.S., §22-1-119.1
A school district board of education of a public school, the state charter school institute for an institute charter school, or the governing board of a nonpublic school may adopt and implement a policy whereby a school may acquire and maintain a supply of opiate antagonists. An employee or agent of the school may, after receiving appropriate training, administer an opiate antagonist on school grounds to assist an individual who is at risk of experiencing an opiate-related drug overdose event
Opioid Treatment for a Person in Custody C.R.S., §17-1-113.4
A correctional facility or private contract prison may make available opioid agonists and opioid antagonists to a person in custody with an opioid use disorder. The correctional facility or private contract prison is strongly encouraged to maintain the treatment of the person throughout the duration of the person’s incarceration, as medically necessary.
As funding and supplies allow, if a person in custody is treated for an opioid use disorder pursuant to this section, the correctional facility or private contract prison shall offer the person, upon release from the facility, at least two doses of an opioid reversal medication, in a form approved by the federal drug administration, and provide education to the person about the appropriate use of the medication.